AU2003274652A8 - Compounds, compositions and methods for modulating fat metabolism - Google Patents

Compounds, compositions and methods for modulating fat metabolism

Info

Publication number
AU2003274652A8
AU2003274652A8 AU2003274652A AU2003274652A AU2003274652A8 AU 2003274652 A8 AU2003274652 A8 AU 2003274652A8 AU 2003274652 A AU2003274652 A AU 2003274652A AU 2003274652 A AU2003274652 A AU 2003274652A AU 2003274652 A8 AU2003274652 A8 AU 2003274652A8
Authority
AU
Australia
Prior art keywords
compositions
compounds
methods
fat metabolism
modulating fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003274652A
Other versions
AU2003274652A1 (en
Inventor
Anne Goupil-Lamy
Georges Gaudriault
Itzik Harosh
Olivier Bousquet
Ahmet Kilinc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ObeTherapy Biotechnology SAS
Original Assignee
ObeTherapy Biotechnology SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObeTherapy Biotechnology SAS filed Critical ObeTherapy Biotechnology SAS
Publication of AU2003274652A1 publication Critical patent/AU2003274652A1/en
Publication of AU2003274652A8 publication Critical patent/AU2003274652A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003274652A 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism Abandoned AU2003274652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42031602P 2002-10-23 2002-10-23
US60/420,316 2002-10-23
PCT/IL2003/000860 WO2004037159A2 (en) 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism

Publications (2)

Publication Number Publication Date
AU2003274652A1 AU2003274652A1 (en) 2004-05-13
AU2003274652A8 true AU2003274652A8 (en) 2004-05-13

Family

ID=32176552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003274652A Abandoned AU2003274652A1 (en) 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism

Country Status (2)

Country Link
AU (1) AU2003274652A1 (en)
WO (1) WO2004037159A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004258750A1 (en) * 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
JP2007537999A (en) * 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド Mutagenic heterocycle
EP1598354A1 (en) 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
ITMI20041567A1 (en) * 2004-07-30 2004-10-30 Maycos Italiana Di Comini Miro "N-ACYLATED DERIVATIVES OF BICARBOXYLIC ACIDS WITH AMINO ACIDS AND WITH HYDROLYZED VEGETABLE PROTEINS AND THEIR APPLICATION IN COSMETIC, DERMO-PHARMACEUTICAL AND PHARMACEUTICAL PRODUCTS"
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
BRPI0608907A2 (en) 2005-05-10 2010-02-17 Itermune Inc stress-activated protein kinase system modulation method
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1885726B1 (en) * 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN1947717B (en) * 2005-10-14 2012-09-26 卓敏 Method for treating neuronal and non-neuronal pain
EP1980237B1 (en) * 2006-01-06 2013-10-02 Ajinomoto Co., Inc. Gelling agent
CN101400682A (en) 2006-01-20 2009-04-01 先灵公司 Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
EP2004656B1 (en) 2006-04-07 2013-07-10 Boehringer Ingelheim International GmbH Thienopyrimidines having mnk1 /mnk2 inhibiting activity for pharmaceutical compositions
WO2007139497A1 (en) * 2006-05-30 2007-12-06 Aprea Ab Levoglucosenone derivatives for the treatment of disorders such as cancer, autoimmune diseases and heart diseases.
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
US20080009508A1 (en) * 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
EP2164500B1 (en) * 2007-05-25 2013-12-04 Idogen AB The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
KR100881137B1 (en) 2007-08-07 2009-02-02 충남대학교산학협력단 New pig pheromonal compounds, their preparation method and a composite for estrus induction
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN103983627A (en) * 2008-06-17 2014-08-13 韩国巴斯德研究所 Pyridopyrimidine compounds as anti-tubercular agents
WO2010023181A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
KR100883548B1 (en) * 2008-10-15 2009-02-13 충남대학교산학협력단 Pig pheromonal compounds, their preparation method and a composite for estrus induction containing it
WO2010096115A1 (en) 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
FR2940611B1 (en) 2008-12-30 2012-01-13 Oreal ASSOCIATION OF MONOSACCHARIDES AND ADENOSINE AND ITS USE IN COSMETICS
UA112284C2 (en) * 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі 5-fluoro-pyrimidinone derivatives
EP2462133B1 (en) * 2009-08-07 2014-09-24 Dow AgroSciences LLC 5-fluoro-2-oxopyrimidine- 1(2h)-carboxylate derivatives as fungicides
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
FR2951639B1 (en) 2009-10-22 2011-11-04 Oreal USE OF ADENOSINE AND / OR ONE OF ITS DERIVATIVES AS A TREATMENT AGENT FOR HUMAN TRANSPIRATION
CA2785834A1 (en) * 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
MX2012009851A (en) 2010-02-26 2012-09-12 Boehringer Ingelheim Int Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions.
MX2012009735A (en) 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having mnkl/ mnk2 inhibiting activity for pharmaceutical compositions.
UY33241A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
US20130324461A1 (en) * 2010-08-26 2013-12-05 Michail V. Sitkovsky Methods and compositions for preventing or treating obesity
AP2014007621A0 (en) 2011-11-11 2014-05-31 Pfizer 2-Thiopyrimidinones
BR112014014740B1 (en) 2011-12-22 2021-08-24 Alios Biopharma, Inc NUCLEOSIDE COMPOUNDS, NUCLEOTIDES AND THEIR ANALOGUES, THEIR USE AND PHARMACEUTICAL COMPOSITION
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2861611T (en) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
MX2015005500A (en) * 2012-10-29 2016-02-09 Cocrystal Pharma Inc Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer.
CA2894542C (en) 2012-12-21 2023-10-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PL2938194T3 (en) 2012-12-28 2020-09-21 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxylate derivatives
CN104884062B (en) 2012-12-28 2018-11-06 阿达玛马克西姆股份有限公司 Fluoro- -1 (the 2h)-carboxamides derivatives of 4- imino groups -3- methyl -2- oxos -3,4- dihydro-pyrimidins of N- (substituted) -5-
ES2874475T3 (en) 2012-12-31 2021-11-05 Adama Makhteshim Ltd Derivatives of 3,4-dihydropyrimidin-2 (1h) -one 3-alkyl-5-fluoro-4-iminosubstituted as fungicides
SG11201602595TA (en) 2013-10-11 2016-04-28 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
KR102373700B1 (en) 2014-04-02 2022-03-11 인터뮨, 인크. Anti-fibrotic pyridinones
AU2016220049C1 (en) 2015-02-18 2021-02-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
PE20180503A1 (en) 2015-05-05 2018-03-09 Pfizer 2-THIOPYRIMIDINONES
CN109503587B (en) * 2017-09-14 2022-01-11 辽宁利锋科技开发有限公司 Anti-tumor effect and application of diheterocyclic triazole nucleoside analogue
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
JP7429799B2 (en) 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド antiviral compounds
TWI775313B (en) 2020-02-18 2022-08-21 美商基利科學股份有限公司 Antiviral compounds
AU2022256476A1 (en) 2021-04-16 2023-10-12 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN115501235B (en) * 2021-08-02 2023-11-07 中山大学·深圳 Application of compound in preparation of medicine for preventing and treating demyelinating diseases
WO2023044104A1 (en) * 2021-09-17 2023-03-23 Emory University Phosphoramidates for the treatment of hepatitis b virus

Also Published As

Publication number Publication date
WO2004037159A3 (en) 2004-07-15
WO2004037159A2 (en) 2004-05-06
AU2003274652A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003274652A8 (en) Compounds, compositions and methods for modulating fat metabolism
EP1477070A4 (en) Fat composition
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) Compounds, methods and compositions
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
HK1070656A1 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
HK1082380A1 (en) Fat composition for spread
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1646382A4 (en) Compounds, compositions and methods
AU2003299612A8 (en) Compounds, compositions and methods
EP1542699A4 (en) Compounds, compositions, and methods employing same
IL167936A0 (en) Compounds, compositions,and methods
AU2003252324A1 (en) Fat composition
AU2003219788A8 (en) Methods and composition for modulating type i muscle formation using pgc-1alpha-
EP1572944A4 (en) Methods and compositions for modulating xbp-1 activity
AU2003256805A8 (en) Compounds compositions and methods
ZA200605983B (en) Nutritional composition for would healing
AU2003290507A8 (en) Compounds, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
EP1680420A4 (en) Compounds, compositions, and methods
EP1594849A4 (en) Compounds, compositions, and methods
EP1620092A4 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase